99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study.
PURPOSE: Radiolabelled interleukin-2 is a radiopharmaceutical used for the study of chronic inflammatory processes. (123)I-labelled interleukin-2 has successfully been used in a large number of patients affected by several immune-mediated diseases. (123)I, however, is expensive and not readily avai...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2008
|
| _version_ | 1797074120819605504 |
|---|---|
| author | Chianelli, M Mather, S Grossman, A Sobnak, R Fritzberg, A Britton, K Signore, A |
| author_facet | Chianelli, M Mather, S Grossman, A Sobnak, R Fritzberg, A Britton, K Signore, A |
| author_sort | Chianelli, M |
| collection | OXFORD |
| description | PURPOSE: Radiolabelled interleukin-2 is a radiopharmaceutical used for the study of chronic inflammatory processes. (123)I-labelled interleukin-2 has successfully been used in a large number of patients affected by several immune-mediated diseases. (123)I, however, is expensive and not readily available. We have, therefore, developed a method for labelling interleukin-2 with (99m)Tc to high specific activity based on the use of an N(3)S bifunctional chelating agent. In this paper, we describe the results obtained with (99m)Tc-interleukin-2 in a series of eight normal subjects and of 12 patients with autoimmune thyroid diseases. METHODS: Biodistribution, pharmacokinetics, haematological and systemic toxicity, radiation absorbed dose and in vivo targeting were studied. RESULTS: Results showed rapid plasma clearance of (99m)Tc-interleukin-2 with retention mainly in the kidneys. Biodistribution and kinetics were similar to that observed for (123)I-interleukin-2. No acute systemic toxicity was found; a small decrease in peripheral blood lymphocytes was observed in the first hours only in patients, but it was mild and transient. (99m)Tc-interleukin-2 accumulated, to varying extents, in the thyroid of all patients affected by autoimmune thyroid diseases but not in the thyroid of normal subjects. The effective dose equivalent of a diagnostic activity of (99m)Tc-interleukin-2 (185 MBq) was 1.35 mSv. No correlation was observed between thyroid autoantibodies and uptake of (99m)Tc-interleukin-2. CONCLUSIONS: The use of (99m)Tc-interleukin-2 is safe and simple; the favourable dosimetry and biodistribution and the rapid clearance make it potentially useful for the study of chronic inflammatory diseases such as autoimmune thyroid disease. |
| first_indexed | 2024-03-06T23:31:45Z |
| format | Journal article |
| id | oxford-uuid:6c4591ac-40e6-441f-bc7f-a1e001ad0514 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:31:45Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:6c4591ac-40e6-441f-bc7f-a1e001ad05142022-03-26T19:09:41Z99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6c4591ac-40e6-441f-bc7f-a1e001ad0514EnglishSymplectic Elements at Oxford2008Chianelli, MMather, SGrossman, ASobnak, RFritzberg, ABritton, KSignore, A PURPOSE: Radiolabelled interleukin-2 is a radiopharmaceutical used for the study of chronic inflammatory processes. (123)I-labelled interleukin-2 has successfully been used in a large number of patients affected by several immune-mediated diseases. (123)I, however, is expensive and not readily available. We have, therefore, developed a method for labelling interleukin-2 with (99m)Tc to high specific activity based on the use of an N(3)S bifunctional chelating agent. In this paper, we describe the results obtained with (99m)Tc-interleukin-2 in a series of eight normal subjects and of 12 patients with autoimmune thyroid diseases. METHODS: Biodistribution, pharmacokinetics, haematological and systemic toxicity, radiation absorbed dose and in vivo targeting were studied. RESULTS: Results showed rapid plasma clearance of (99m)Tc-interleukin-2 with retention mainly in the kidneys. Biodistribution and kinetics were similar to that observed for (123)I-interleukin-2. No acute systemic toxicity was found; a small decrease in peripheral blood lymphocytes was observed in the first hours only in patients, but it was mild and transient. (99m)Tc-interleukin-2 accumulated, to varying extents, in the thyroid of all patients affected by autoimmune thyroid diseases but not in the thyroid of normal subjects. The effective dose equivalent of a diagnostic activity of (99m)Tc-interleukin-2 (185 MBq) was 1.35 mSv. No correlation was observed between thyroid autoantibodies and uptake of (99m)Tc-interleukin-2. CONCLUSIONS: The use of (99m)Tc-interleukin-2 is safe and simple; the favourable dosimetry and biodistribution and the rapid clearance make it potentially useful for the study of chronic inflammatory diseases such as autoimmune thyroid disease. |
| spellingShingle | Chianelli, M Mather, S Grossman, A Sobnak, R Fritzberg, A Britton, K Signore, A 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study. |
| title | 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study. |
| title_full | 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study. |
| title_fullStr | 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study. |
| title_full_unstemmed | 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study. |
| title_short | 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study. |
| title_sort | 99mtc interleukin 2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases a feasibility study |
| work_keys_str_mv | AT chianellim 99mtcinterleukin2scintigraphyinnormalsubjectsandinpatientswithautoimmunethyroiddiseasesafeasibilitystudy AT mathers 99mtcinterleukin2scintigraphyinnormalsubjectsandinpatientswithautoimmunethyroiddiseasesafeasibilitystudy AT grossmana 99mtcinterleukin2scintigraphyinnormalsubjectsandinpatientswithautoimmunethyroiddiseasesafeasibilitystudy AT sobnakr 99mtcinterleukin2scintigraphyinnormalsubjectsandinpatientswithautoimmunethyroiddiseasesafeasibilitystudy AT fritzberga 99mtcinterleukin2scintigraphyinnormalsubjectsandinpatientswithautoimmunethyroiddiseasesafeasibilitystudy AT brittonk 99mtcinterleukin2scintigraphyinnormalsubjectsandinpatientswithautoimmunethyroiddiseasesafeasibilitystudy AT signorea 99mtcinterleukin2scintigraphyinnormalsubjectsandinpatientswithautoimmunethyroiddiseasesafeasibilitystudy |